MedTrace Logo

A Study of DA-8159 in Subjects With Erectile Dysfunction

NCT00282607 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2007-02-28

No results posted yet for this study

Summary

The purpose of this study will be to evaluate the clinical efficacy and safety of DA-8159, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of subjects with erectile dysfunction (ED).

Conditions

Interventions

DRUG

DA-8159

Sponsors & Collaborators

  • Dong-A PharmTech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • James L Yeager, RPh., Ph.D.

  • Harin Padma-Nathan, MD · The Male Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282607 on ClinicalTrials.gov